Mini Oral session - Sarcoma Mini Oral session

406O - VEGFR2 Polymorphisms as Novel Biomarker of Anti-angiogenic Therapy for Pediatric and Young Adult Sarcoma

Presentation Number
406O
Lecture Time
12:05 PM - 12:10 PM
Speakers
  • Qiyuan Bao
Location
Room 311, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
11:40 AM - 12:20 PM
Authors
  • Qiyuan Bao
  • Yuehao Hu
  • Junxiang Wen
  • Yuhui Shen
  • Weibin Zhang

Abstract

Background

The impact of germline mutations of the angiogenesis pathways on the therapeutic response has been extensively studied for the carcinoma population. However, such information is almost unknown for pediatric and young adult’s sarcoma, for which the field has seen the rapid growing popularity of the use of the anti-angiogenic therapy.

Methods

In this study, we retrospectively analyzed 79 tissue sarcoma patients less than 45 yrs receiving anti-angiogenic therapy (apatinib). In 67 (84%) of these patients, twenty previously reported single nuclear polymorphism (SNPs) in angiogenesis pathway were genotyped to screen for potential toxicity and predictive biomarkers.

Results

The mean 6 mo PFS rate was 64%, with the duration of response varying from no response to more than 26 months. Multivariate analysis indicated that hand-foot reactions, hair depigmentation and spontaneously pneumothorax (SP) remain independent toxicity biomarker for greater PFS. Interestingly, we observed a strong correlation of ITGA2 rs1126643 polymorphism vs surgical wound complications (C/C 4% vs C/T 24% vs T/T 33%, p = 0.008) as well as SP (C/C 13.8% vs C/T 36.4% vs T/T 66%), suggesting that Integrin mechanism might underline both toxicities. Moreover, VEGFR2 rs2071559 polymorphism remains the only sensitivity biomarker for mPFS (mutation vs WT, 12 mo vs 5 mo), regardless of the sarcoma subtypes. Surprisingly, such mutations were to be associated with the incidence of hair depigmentation (R = 0.398, p = 0.026), further supporting that hair discoloration is a mechanism-based toxicity biomarker. Moreover, a significant higher frequecies of such two mutations (0.53 for ITGA polymorphism, 0.59 for VEGFR2 polymorphism) in our cohort than general Han Chinese (1000G project database) suggest a theoretical impact on the sarcomagenesis.

Conclusions

Our study is the first one examining the angiogenesis germline polymorphism for the younger population in bone and soft tissue cancer. VEGFR2 (rs2071559) as well as ITGA (rs1126643) might serve as pan-sarcoma biomarkers for VEGFR2 targeted therapy and warrant further validation for its biological and clinical implications.

Legal entity responsible for the study

Ruijin Hospital.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Collapse
Mini Oral session - Sarcoma Mini Oral session

Discussion led by moderators

Lecture Time
11:50 AM - 12:00 PM
Speakers
  • Tom Wei-Wu Chen
  • Silvia Stacchiotti
  • Aisha Miah
Location
Room 311, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
11:40 AM - 12:20 PM
Authors
  • Tom Wei-Wu Chen
  • Silvia Stacchiotti
  • Aisha Miah
Surgical management of ovarian cancer Challenge Your Expert session

Surgical Management of Ovarian Cancer

Lecture Time
11:45 AM - 12:00 PM
Speakers
  • Christian Marth
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
11:45 AM - 12:30 PM
Authors
  • Christian Marth
Surgical management of ovarian cancer Challenge Your Expert session

Discussion

Lecture Time
12:00 PM - 12:30 PM
Speakers
  • Amita Maheshwari
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
11:45 AM - 12:30 PM
Authors
  • Amita Maheshwari
Locally advanced nasopharyngeal carcinoma (LA NPC): Asian and European perspectives Challenge Your Expert session

Locally advanced nasopharyngeal carcinoma (LA NPC): Asian and European perspectives

Lecture Time
11:45 AM - 12:15 PM
Speakers
  • Anthony T. Chan
  • Pierre Blanchard
Location
Room 324, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
11:45 AM - 12:30 PM
Authors
  • Anthony T. Chan
  • Pierre Blanchard
Immunotherapy in GU cancers: Focus on kidney and bladder cancers Challenge Your Expert session

Kidney

Lecture Time
11:45 AM - 11:55 AM
Speakers
  • Yu Li Su
Location
Summit 2, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
11:45 AM - 12:30 PM
Authors
  • Yu Li Su
Locally advanced nasopharyngeal carcinoma (LA NPC): Asian and European perspectives Challenge Your Expert session

Discussion

Lecture Time
12:15 PM - 12:30 PM
Location
Room 324, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
11:45 AM - 12:30 PM
Optimal sequence and treatment choice in osimertinib failure Challenge Your Expert session

Optimal sequence and treatment choice in osimertinib failure

Lecture Time
11:45 AM - 12:00 PM
Speakers
  • Tony S.K. Mok
Location
Hall 404, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
11:45 AM - 12:30 PM
Authors
  • Tony S.K. Mok
Immunotherapy in GU cancers: Focus on kidney and bladder cancers Challenge Your Expert session

Bladder

Lecture Time
11:55 AM - 12:05 PM
Speakers
  • Ravindran Kanesvaran
Location
Summit 2, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
11:45 AM - 12:30 PM
Authors
  • Ravindran Kanesvaran
Optimal sequence and treatment choice in osimertinib failure Challenge Your Expert session

Discussion

Lecture Time
12:00 PM - 12:30 PM
Location
Hall 404, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
11:45 AM - 12:30 PM
Immunotherapy in GU cancers: Focus on kidney and bladder cancers Challenge Your Expert session

Discussion

Lecture Time
12:05 PM - 12:30 PM
Location
Summit 2, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
11:45 AM - 12:30 PM

Introduction (ID 1779)